Semaglutide

Compounded semaglutide (Sema/B₁₂) contains the same active ingredient as certain brand-name medications and is prepared by a state-licensed sterile compounding pharmacy. It features the addition of vitamin B₁₂ for enhanced energy support. Note: Compounded medications are not FDA-approved. The FDA does not review compounded medications for safety or efficacy.

Individual results vary significantly based on factors like starting weight, diet, exercise, adherence to treatment, and individual physiology. In the STEP 1 clinical trial, participants lost an average of 14.9% of their body weight over 68 weeks. Your provider will set realistic expectations during your consultation. No specific outcomes are guaranteed.

Semaglutide mimics the naturally occurring hormone GLP-1, which is released after eating. It works through three pathways: reducing appetite signals in the brain, slowing gastric emptying to prolong fullness, and enhancing glucose-dependent insulin secretion. This comprehensive approach helps reduce caloric intake naturally.

The most common side effects are gastrointestinal: nausea, diarrhea, vomiting, constipation, and decreased appetite. These are typically mild-to-moderate and often diminish as your body adjusts. The gradual dose escalation protocol helps minimize these effects. Your provider will discuss all potential risks and monitor you throughout treatment.

Semaglutide is an excellent choice for patients seeking proven, cost-effective weight loss. At $147/month vs $249/month for Tirzepatide, it offers significant savings while still delivering clinically proven results. It's ideal for first-time GLP-1 users and those who want a well-established treatment with extensive clinical data.

Semaglutide is ideal for adults with BMI ≥30 (or ≥27 with weight-related comorbidities) who are serious about sustainable weight loss. It's particularly suited for first-time GLP-1 users, those seeking a proven and cost-effective option, patients with Type 2 diabetes or prediabetes, and individuals who prefer a gradual, well-studied approach.

Treatment begins at 0.25mg weekly for 4 weeks, then increases to 0.5mg, 1.0mg, 1.7mg, and finally 2.4mg — each step lasting 4 weeks. This gradual approach over 16+ weeks allows your body to adjust and minimizes side effects while optimizing weight loss. Your physician will customize the titration based on your individual response.

Yes, patients can switch between GLP-1 medications under medical supervision. Some patients switch to Semaglutide for cost savings while maintaining their weight loss. The transition should be managed by your provider who will determine the appropriate starting dose based on your current treatment.